Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749001 | 0.83 | TDP1 (0.38) | ALDH1A1TSHRALOX12APP | |
| SCHEMBL30749122 | 0.72 | TNK2 (0.36) | TNK2BTK | |
| SCHEMBL30748936 | 0.69 | CCNE2 (0.41) | APP | |
| SCHEMBL30749065 | 0.68 | PDE4A (0.39) | ALDH1A1TSHRAPP | |
| SCHEMBL30749128 | 0.68 | CHRM4 (0.40) | ALDH1A1TSHRACACBGRM2ABL1 | |
| SCHEMBL30748909 | 0.66 | ACACB (0.37) | ACACBHRH3 | |
| SCHEMBL30748831 | 0.64 | HRH3 (0.36) | ALDH1A1TSHRALOX12ACACBHRH3 | |
| SCHEMBL30748758 | 0.61 | APP (0.37) | APP | |
| SCHEMBL623629 | 0.60 | PARP10 (0.53) | BTKALDH1A1TSHRPARP10GRM2 | |
| SCHEMBL26012610 | 0.60 | PARP10 (0.53) | BTKALDH1A1TSHRPARP10GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | TNK2 1723/4885BTK 1727/4885ALDH1A1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.